Equvirab-D Capsule SR

Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The sustained-release (SR) formulation ensures a prolonged therapeutic effect, optimizing drug plasma concentration and enhancing patient compliance by reducing dosing frequency.

Equvirab-D Capsule SR is indicated for patients requiring combined prokinetic and acid-suppressive therapy to improve upper gastrointestinal motility and reduce acid secretion simultaneously. It should be administered under medical supervision, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with cardiac arrhythmias or electrolyte imbalances.

Common adverse effects may include headache, dry mouth, abdominal cramps, and, rarely, extrapyramidal symptoms. This combination offers a comprehensive approach to managing complex gastrointestinal conditions by targeting multiple pathophysiological mechanisms.